the benefits of bispecific antibodies for treating multiple myeloma
Published 3 years ago • 201 plays • Length 6:35Download video MP4
Download video MP3
Similar videos
-
2:17
the role of car t-cell therapy for treating myeloma in the era of bispecific antibodies
-
1:45
using the available repertoire of bispecific antibodies for treating multiple myeloma
-
1:48
the potential of bispecific antibody-containing combinations in patients with b-cell lymphomas
-
1:49
the benefit of bispecific antibodies & car-t therapy in triple class-exposed multiple myeloma
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
6:17
myeloma made simple: bispecific antibodies made simple | bispecific antibodies for myeloma treatment
-
6:09
bispecific antibodies | high impact topic (hit)
-
5:06
bispecific antibodies: late side effects
-
1:45
the advent of bispecific antibodies for multiple myeloma
-
7:05
developments in the use of bispecific antibodies in myeloma and challenges in this space
-
2:25
advancements and challenges in bispecific antibodies for the treatment of b-nhl
-
4:15
bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
-
1:20
a comparison of bispecific antibodies emerging in multiple myeloma
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
1:42
how to best sequence bispecific antibodies and car-t therapy in multiple myeloma
-
2:22
outcomes and management of patients with r/r myeloma who progress on bispecific antibodies
-
2:55
bispecific antibodies for myeloma: highlights from ash 2020
-
2:38
approaching the treatment of patients with lbcl who relapse after bispecific antibodies
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:22
risk of infection in patients with multiple myeloma treated with bispecific antibodies
-
3:37
bispecific antibodies in multiple myeloma: their current role and the future
-
2:22
immuno-oncology and the future of multiple myeloma treatment